FDA Approves UroGen's ZUSDURI for Recurrent Low-Grade Bladder Cancer
UroGen Pharma's ZUSDURI, a new intravesical mitomycin formulation using sustained-release technology, has been approved by the FDA for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, offering a non-surgical alternative to TURBT with promising trial results showing high response rates.